Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 -0.17%10 PS Ratio is 13.34 as of Aug. 02, 2026, which is 58% below its 10-year median of 31.50. GuruFocus rates ROCO:7808 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 931 Biotechnology companies, Bionet Therapeutics ranks worse than 59.72% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bionet Therapeutics's share price is NT$29.45.
Bionet Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.21. Hence, Bionet Therapeutics's PS Ratio for today is 13.34.
Good Sign:
Bionet Therapeutics Corp stock PS Ratio (=13.66) is close to 2-year low of 13.66.
The historical rank and industry rank for Bionet Therapeutics's PS Ratio or its related term are showing as below:
ROCO:7808'
s PS Ratio Range Over the Past 10 Years
Min: 13 Med: 31.5 Max: 141.13
Current: 13.34
During the past 4 years, Bionet Therapeutics's highest PS Ratio was 141.13. The lowest was 13.00. And the median was 31.50.
ROCO:7808's PS Ratio is ranked worse than 59.72% of 931
companies
in the Biotechnology industry
Industry Median: 8.9
vs ROCO:7808: 13.34
Bionet Therapeutics (ROCO:7808) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Bionet Therapeutics PS Ratio Related Terms
Bionet Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Bionet Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Bionet Therapeutics's Share Price of today is NT$29.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bionet Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Bionet Therapeutics (ROCO:7808) has a PS Ratio of 13.34 as of Aug. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bionet Therapeutics and its competitors. This is 58% below median its historical median of 31.50. Over the past decade, Bionet Therapeutics' PS Ratio has ranged from 13.00 to 141.13. According to the industry distribution chart, Bionet Therapeutics ranks #556 out of 931 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Bionet Therapeutics' PS Ratio too high?
Bionet Therapeutics' current PS Ratio of 13.34 is 58% below median its 10-year median of 31.50. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 141.13. The Biotechnology industry median PS Ratio is 8.90. Bionet Therapeutics' value of 13.34 is 49.9% above this industry median. Based on the distribution chart, Bionet Therapeutics ranks #556 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bionet Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #556 out of 931 companies for PS Ratio. This places Bionet Therapeutics in the lower half of its industry. The industry median PS Ratio is 8.90. Bionet Therapeutics' value of 13.34 is 49.9% above this benchmark. Historically, Bionet Therapeutics' own PS Ratio has ranged from 13.00 to 141.13 over the past decade. While the company's 10-year median is 31.50 vs. the industry median of 8.90, Bionet Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 8.90, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet Therapeutics's current PS Ratio of 13.34 is 49.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bionet Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet Therapeutics's current PS Ratio is 13.34, which is 58% below median its own 10-year median of 31.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current PS Ratio of 13.34. The current PS Ratio is 13.34, which is 58% below median its 10-year median of 31.50 and 49.9% above the Biotechnology industry median of 8.90. Bionet Therapeutics' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current PS Ratio is 13.34 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
10GF Score
Get the complete analysis for ROCO:7808
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
